Margaret Rosenfeld

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi request reprint Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
  2. doi request reprint Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, WA 98105, USA
    J Cyst Fibros 11:456-7. 2012
  3. pmc Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, Washington 98105, USA
    JAMA 307:2269-77. 2012
  4. pmc Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington School of Medicine, Seattle Children s Hospital, 4800 Sandpoint Way NE, Seattle, WA 98105, USA
    Pediatr Pulmonol 46:666-71. 2011
  5. ncbi request reprint An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Proc Am Thorac Soc 4:299-301. 2007
  6. doi request reprint Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
  7. pmc Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
  8. pmc Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
  9. pmc Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
  10. pmc Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 48:943-53. 2013

Research Grants

Detail Information

Publications41

  1. doi request reprint Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
    ..We aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations...
  2. doi request reprint Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, WA 98105, USA
    J Cyst Fibros 11:456-7. 2012
    ..To describe the prevalence of the CF pathogens Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae in OP cultures from healthy children...
  3. pmc Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, Washington 98105, USA
    JAMA 307:2269-77. 2012
    ..Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF...
  4. pmc Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington School of Medicine, Seattle Children s Hospital, 4800 Sandpoint Way NE, Seattle, WA 98105, USA
    Pediatr Pulmonol 46:666-71. 2011
    ..Prior to undertaking a clinical trial of HS efficacy in young children with CF, tolerability, adherence, and safety must be established...
  5. ncbi request reprint An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Proc Am Thorac Soc 4:299-301. 2007
    ..Finally, choosing appropriate endpoints for specific indications will be discussed...
  6. doi request reprint Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
    ..The EPIC Observational Study is an ongoing prospective cohort study investigating risk factors for and clinical outcomes associated with early Pseudomonas aeruginosa (Pa) acquisition in young children with cystic fibrosis (CF)...
  7. pmc Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
    ..Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood...
  8. pmc Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
    ..To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF)...
  9. pmc Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
    ..The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown...
  10. pmc Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 48:943-53. 2013
    ....
  11. ncbi request reprint Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 167:841-9. 2003
    ..We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis...
  12. pmc Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, Seattle Children s Hospital, WA 98104, USA
    Arch Pediatr Adolesc Med 165:847-56. 2011
    ..To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection...
  13. pmc Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection
    Tamara D Simon
    Department of Pediatrics, University of Washington Seattle Children s Hospital, Seattle, WA, USA
    Pediatr Infect Dis J 31:551-6. 2012
    ..The object of this study was to determine whether cerebrospinal fluid (CSF) shunt revision(s) are associated with increased risk of CSF shunt infection, after adjusting for baseline factors that contribute to infection risk...
  14. pmc Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin
    Jennifer Ruddy
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Aerosol Med Pulm Drug Deliv 26:69-75. 2013
    ....
  15. ncbi request reprint Overview of published evidence on outcomes with early diagnosis from large US observational studies
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98105, USA
    J Pediatr 147:S11-4. 2005
    ..Taken together, these observational studies provide indirect evidence that diagnosis by means of newborn screening may improve the pulmonary health and survival of patients with CF...
  16. doi request reprint Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis
    Don B Sanders
    Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Pediatr Pulmonol 46:393-400. 2011
    ..The purpose of this study was to determine the association between the frequency of pulmonary exacerbations and subsequent forced expiratory volume in 1 sec (FEV(1) ) decline in adults and children with CF...
  17. ncbi request reprint Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Julia Emerson
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, USA
    Pediatr Pulmonol 34:91-100. 2002
    ..These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention...
  18. doi request reprint Lung function from infancy to preschool in a cohort of children with cystic fibrosis
    Lyndia C Brumback
    Dept of Biostatistics, University of Washington, Children s Hospital Research Institute, Seattle, WA 98195 7232, USA
    Eur Respir J 41:60-6. 2013
    ..5), FEF(25-75%) and forced vital capacity). Recent P. aeruginosa infection and cough are associated with lower lung function in children with CF. Significant inter-individual variability in lung function remains to be explained...
  19. ncbi request reprint Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington, Seattle, USA
    Curr Opin Pulm Med 9:492-7. 2003
    ..To summarize the pathophysiology of, risk factors for, and outcomes of early Pseudomonas aeruginosa (Pa) infection in CF; to review the results of trials of early intervention and to describe treatment options for early Pa infection...
  20. doi request reprint Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation
    Don B Sanders
    Department of Pediatrics, American Family Children s Hospital, 600 Highland Avenue, Madison, WI 53792 9988, USA
    Am J Respir Crit Care Med 182:627-32. 2010
    ..Patients with cystic fibrosis periodically experience pulmonary exacerbations. Previous studies have noted that some patients' lung function (FEV(1)) does not improve with treatment...
  21. ncbi request reprint Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis
    Miriam M Treggiari
    Department of Anesthesiology, Harborview Medical Center, University of Washington School of Medicine, Seattle, Washington 98104, USA
    Pediatr Pulmonol 42:751-6. 2007
    ....
  22. pmc Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement
    Tamara D Simon
    Department of Pediatrics, University of Washington Seattle Children s Hospital, Seattle, Washington, USA
    J Neurosurg Pediatr 9:54-63. 2012
    ..The object of this study was to identify baseline factors at the time of initial CSF shunt placement that are independently associated with subsequent surgery...
  23. pmc Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints
    Stephanie D Davis
    Department of Pediatrics, North Carolina Children s Hospital, University of North Carolina at Chapel Hill, USA
    Am J Respir Crit Care Med 182:1387-97. 2010
    ..The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures...
  24. ncbi request reprint Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials
    Nicole Mayer-Hamblett
    Department of Pediatrics and Biostatistics, University of Washington, Seattle, WA, USA
    Contemp Clin Trials 36:99-105. 2013
    ..Our hypothesis was that acute antibiotics given for illnesses not meeting the PE definition may alter estimates of treatment effect that do not account for this antibiotic use...
  25. ncbi request reprint Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 166:1550-5. 2002
    ..Better clinical predictors of short-term mortality among patients with CF are needed...
  26. ncbi request reprint Cystic fibrosis pulmonary exacerbations
    Thomas Ferkol
    Department of Pediatrics, Cell Biology and Physiology, Washington University School of Medicine, St Louis Children s Hospital, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Pediatr 148:259-64. 2006
  27. ncbi request reprint The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study
    Jason S Debley
    Department of Pediatrics, Division of Pulmonary Medicine, University of Washington, Seattle, Washington 98105, USA
    J Pediatr 147:233-8. 2005
    ..To determine the prevalence of ibuprofen-sensitive asthma in school-aged children with mild or moderate persistent asthma...
  28. pmc Endpoints for clinical trials in young children with cystic fibrosis
    Stephanie D Davis
    Division of Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Proc Am Thorac Soc 4:418-30. 2007
    ..Further development of these outcomes measures will enable clinical trials in the youngest CF population with the objective of improving long-term prognosis...
  29. ncbi request reprint Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes
    David L Veenstra
    Institute for Public Health Genetics, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 9:695-704. 2007
    ..Although the A1555G variant is very rare, it seems to confer a high risk of severe hearing loss in patients exposed to aminoglycosides...
  30. doi request reprint Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations
    Don B Sanders
    Pediatric Pulmonary Division, Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
    Pediatr Pulmonol 43:1142-6. 2008
    ..To compare the within day variation of spirometry between hospital admission, discharge, and outpatient follow up among children with cystic fibrosis (CF) hospitalized for a pulmonary exacerbation...
  31. doi request reprint Therapeutic bilateral lung lavage in a child with pulmonary alveolar proteinosis
    Robert M DiBlasi
    Respiratory Care Department, Seattle Children s Hospital, Seattle, WA, USA
    Pediatr Crit Care Med 11:e28-31. 2010
    ..We successfully and safely performed therapeutic bilateral lung lavage and obtained lung mechanics measurements in a child with pulmonary alveolar proteinosis...
  32. pmc Evaluation of microbial bacterial and fungal diversity in cerebrospinal fluid shunt infection
    Tamara D Simon
    Department of Pediatrics, University of Washington Seattle Children s Hospital, Seattle, Washington, United States of America Center for Clinical and Translational Research, Seattle Children s Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e83229. 2014
    ..Improved diagnostic and therapeutic approaches are required, and culture-independent molecular approaches to cerebrospinal fluid shunt infections have not been described...
  33. ncbi request reprint Update on cystic fibrosis epidemiology
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Curr Opin Pulm Med 10:510-4. 2004
    ..This review is not meant to be comprehensive, but highlights selected studies, many of which have particular relevance to the growing number of older CF patients...
  34. ncbi request reprint Opportunities and pitfalls of registry data for clinical research
    Kevin J Psoter
    Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195, USA
    Paediatr Respir Rev 14:141-5. 2013
    ..We conclude with a discussion of a practical approach when considering registry data for clinical research. ..
  35. pmc Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children
    Teresa J Tuan
    Department of Pediatrics, University of California at San Francisco, San Francisco, CA, USA
    Pediatr Infect Dis J 30:731-5. 2011
    ..A small group of children have second and even more cerebrospinal fluid (CSF) shunt infections (SIs). We sought to describe the treatment approaches used for, and the microbiology of, repeated SIs...
  36. ncbi request reprint Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system
    David E Geller
    The Nemours Children s Clinic, 83 W Columbia St, Orlando, FL 32806 1101, USA
    Chest 123:28-36. 2003
    ..Second, we wanted to ascertain which AeroDose-delivered tobramycin dose is equivalent to the standard 300-mg dose administered with the PARI LC PLUS...
  37. ncbi request reprint Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report
    Anne Marie Comeau
    New England Newborn Screening Program and Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Pediatrics 119:e495-518. 2007
    ....
  38. ncbi request reprint Improved survival among young patients with cystic fibrosis
    Michal Kulich
    Department of Biostatistics, University of Washington, Seattle 98195 7232, USA
    J Pediatr 142:631-6. 2003
    ..To investigate age-specific trends in survival among US patients with cystic fibrosis between 1985 and 1999 and to assess whether survival in female patients with cystic fibrosis has improved relative to survival in male patients...
  39. ncbi request reprint Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs
    Scott D Grosse
    Office of the Director, National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia 30333, USA
    MMWR Recomm Rep 53:1-36. 2004
    ..States should consider the magnitude of benefits and costs and the need to minimize risks through careful planning and implementation, including ongoing collection and evaluation of outcome data...
  40. ncbi request reprint Disease-specific reference equations for lung function in patients with cystic fibrosis
    Michal Kulich
    Department of Probability and Mathematical Statistics, Charles University, Prague, Czech Republic
    Am J Respir Crit Care Med 172:885-91. 2005
    ..There are limitations to comparing the lung function of a patient with CF to that of healthy control subjects, and potential advantages to comparing it to that of other patients with CF...
  41. ncbi request reprint Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis
    Scott D Grosse
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    J Pediatr 149:362-6. 2006
    ..To estimate the population impact of child mortality as a result of cystic fibrosis (CF) potentially preventable by newborn screening...

Research Grants5

  1. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2000
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..
  2. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2001
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..
  3. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2002
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..
  4. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2003
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..
  5. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2004
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..